Resmetirom, GLP-1, or Both? How MASH Patients Compare

Two therapies now have accelerated FDA approval for MASH with moderate to advanced fibrosis: resmetirom, a liver-directed THR-β agonist, and semaglutide 2.4 mg, a GLP-1 receptor agonist. Inovalon researchers analyzed real-world claims to see who receives each therapy and how often patients have claims for both.

What the Data Show

45.6%

Nearly Half of Resmetirom Patients Also Had a GLP-1 RA Claim

Of 6,504 resmetirom-treated patients, 2,963 also had at least one GLP-1 RA claim.*




2,963 also had a GLP-1 RA claim

6,504 resmetirom-treated patients

70% vs. **7%**

Liver Assessment Was More Common Among Resmetirom Users


About 70% of patients starting resmetirom had liver elastography in the prior year, compared with 7% of patients starting a GLP-1 RA alone.



82%

Dual-Therapy Patients Carry the Heaviest Comorbidity Burden

82% of patients with claims for both therapies had type 2 diabetes, compared with 35% of patients on resmetirom alone.



40% vs. **0.5%**

GI/Hepatology Initiated More Resmetirom Prescriptions

GI/hepatology wrote approximately 40% of first resmetirom prescriptions, compared with 0.5% of GLP-1 RA monotherapy prescriptions, which were most often written by primary care providers.**



The Takeaway

Real-world use of resmetirom and GLP-1 RAs reflects distinct patient populations and care pathways. The differences showed up in comorbidities, liver assessment, and prescriber specialty, while payer mix was similar across all three groups.

What EHR and Clinical Notes Add

Claims show which tests were run and which therapies were started. Linking them with EHR data and clinical notes can add what those tests found and why a therapy was started.

01 **Fibrosis Stage**
Clinical notes can document fibrosis stage (F0-F4), an important factor in eligibility for MASH therapies indicated for F2-F3 fibrosis.

02 **Test Results**
FIB-4 scores and elastography measurements provide insight into fibrosis risk and liver stiffness, including how these measures change over time.

03 **Cardiometabolic Profile**
EHR data can add BMI history alongside type 2 diabetes, obesity, and dyslipidemia diagnoses.

04 **Treatment Rationale**
Notes can capture eligibility determinations and the clinical reasoning behind starting a therapy.

Explore the Inovalon and OMNY Health Linked Closed Claims and EHR Dataset →

Talk to our HEOR experts →

About the Research

Real-world claims analysis of Inovalon real-world data (Commercial, Medicare Advantage, and Managed Medicaid claims, March 2023 to March 2026) including patients with a MASH/MASLD diagnosis and a first resmetirom or GLP-1 RA claim between March 2024 and March 2026. Presented at The Liver Meeting 2026.

*Dual therapy means at least one claim for each agent during the study period, not necessarily at the same time.

**Prescriber specialty was not recorded or fell outside these categories for 46% to 49% of prescriptions in each group.

inovalon®

Inovalon and design® and Inovalon® are trademarks of Inovalon, Inc.

INS-26-0844